UCB SA

ENXTBR:UCB Stock Report

Market Cap: €36.3b

UCB Past Earnings Performance

Past criteria checks 1/6

UCB's earnings have been declining at an average annual rate of -17.4%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 1.4% per year. UCB's return on equity is 2.7%, and it has net margins of 4.4%.

Key information

-17.4%

Earnings growth rate

-17.6%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth rate1.4%
Return on equity2.7%
Net Margin4.4%
Next Earnings Update27 Feb 2025

Recent past performance updates

Recent updates

Is UCB (EBR:UCB) A Risky Investment?

Dec 24
Is UCB (EBR:UCB) A Risky Investment?

Why We're Not Concerned About UCB SA's (EBR:UCB) Share Price

Oct 22
Why We're Not Concerned About UCB SA's (EBR:UCB) Share Price

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

Sep 10
These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

Analysts Have Made A Financial Statement On UCB SA's (EBR:UCB) Half-Yearly Report

Jul 28
Analysts Have Made A Financial Statement On UCB SA's (EBR:UCB) Half-Yearly Report

Investors Still Waiting For A Pull Back In UCB SA (EBR:UCB)

Jul 15
Investors Still Waiting For A Pull Back In UCB SA (EBR:UCB)

Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Apr 19
Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Is UCB (EBR:UCB) A Risky Investment?

Mar 27
Is UCB (EBR:UCB) A Risky Investment?

Earnings Tell The Story For UCB SA (EBR:UCB) As Its Stock Soars 26%

Mar 04
Earnings Tell The Story For UCB SA (EBR:UCB) As Its Stock Soars 26%

Revenue & Expenses Breakdown

How UCB makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

ENXTBR:UCB Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 245,4542402,0331,660
31 Mar 245,3182921,9291,645
31 Dec 235,1823431,8241,630
30 Jun 235,1113321,7261,631
31 Mar 235,2793761,7201,651
31 Dec 225,4474201,7141,670
30 Jun 225,8548871,6951,674
31 Mar 225,8169711,6251,652
31 Dec 215,7771,0551,5541,629
30 Sep 215,6479961,5061,631
30 Jun 215,5179361,4581,633
31 Mar 215,4328341,4381,601
31 Dec 205,3477321,4171,569
30 Jun 205,1987431,3681,393
31 Mar 205,0567671,3361,333
31 Dec 194,9137901,3031,272
30 Jun 194,6866521,2121,229
31 Mar 194,6597221,1781,195
31 Dec 184,6327921,1441,161
30 Jun 184,5698721,1051,083
31 Mar 184,5228121,1191,070
31 Dec 174,4747521,1321,057
30 Sep 174,4007081,1381,047
30 Jun 174,3256641,1441,036
31 Mar 174,2366041,1331,028
31 Dec 164,1475431,1221,020
30 Sep 164,0514391,1111,022
30 Jun 163,9553341,0991,023
31 Mar 163,9162991,0981,030
31 Dec 153,8762641,0961,037
30 Sep 153,7732661,069999
30 Jun 153,6702681,042961
31 Mar 153,5071921,011945
31 Dec 143,344115980928
30 Sep 143,206114963905
30 Jun 143,067112946881
31 Mar 143,10097971884

Quality Earnings: UCB has high quality earnings.

Growing Profit Margin: UCB's current net profit margins (4.4%) are lower than last year (6.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: UCB's earnings have declined by 17.4% per year over the past 5 years.

Accelerating Growth: UCB's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: UCB had negative earnings growth (-27.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (9.5%).

Return on Equity

High ROE: UCB's Return on Equity (2.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 08:35
End of Day Share Price 2025/01/02 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

UCB SA is covered by 48 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mark van der GeestABN AMRO Bank N.V.
Kamla SinghAlphaValue
Brian BourdotBarclays